Danish Construction Stock News

Investors may be wondering whether Bavarian Nordic is attractively priced at its current level, or if the recent run has already incorporated most of the value. The stock last closed at kr197.25, with returns of 3.8% over 7 days, 2.4% over 30 days, 2.3% year to date, 30.7% over 1 year, 1.0% over 3 years, and a 31.8% decline over 5 years. Recent news coverage has focused on Bavarian Nordic's role in vaccines and biopharmaceuticals. This has kept attention on the company as investors reassess...

Aktieselskabet Schouw (CPSE:SCHO) is back in focus after recent share price moves, with the stock up 5.9% over the past week yet showing a small loss over the past month. See our latest analysis for Aktieselskabet Schouw. The recent 5.9% 7 day share price return contrasts with a modest 30 day share price decline and a slightly negative year to date performance, while the 1 year total shareholder return of 9.94% points to momentum that has been built over a longer holding period. If this kind...

At its March 25, 2026 AGM, NKT A/S approved an amendment to Article 5.2 of its Articles of Association, confirmed new employee representatives, elected Jens Due Olsen as Chair and René Svendsen-Tune as Deputy Chair, and moved to redeem all remaining securities after acquiring about 85% of the €150,000,000 issue. This combination of capital structure simplification through full security redemption and refreshed governance arrangements could influence how investors assess NKT’s financial...

Genmab (CPSE:GMAB) reports that major shareholder Orbis Investment Management Limited now holds a significant portion of its voting rights. The change in Orbis' voting stake reflects an updated picture of Genmab's shareholder structure. The disclosure highlights a material shift in ownership that may be relevant for investors tracking governance and control. Genmab focuses on developing antibody based therapies, an area that continues to attract attention as large pharma groups look for new...

Recent performance context for Novo Nordisk Novo Nordisk (CPSE:NOVO B) has drawn fresh attention after a mixed stretch in its share performance, with a small gain over the past day contrasting with weaker returns over the month and past 3 months. See our latest analysis for Novo Nordisk. At around DKK231.15 per share, Novo Nordisk’s recent 1 day share price gain contrasts with a weaker year to date share price return of about 30% and a 1 year total shareholder return decline of around 49%...

Jyske Bank (CPSE:JYSK) is back in focus after shareholders advanced plans to cancel treasury shares and reduce nominal share capital, alongside an ongoing share repurchase programme of up to DKK 3b. See our latest analysis for Jyske Bank. These capital return moves come after a mixed period for the stock. A 1-day share price return of 0.82% and 7-day gain of 1.77% contrast with a 30-day share price return of 9.01% and only slightly negative year-to-date performance. The 1-year total...

ISS buyback and dividend move into focus ISS (CPSE:ISS) has put shareholder returns firmly in the spotlight with a new share buyback programme of up to DKK 2.5b and an annual dividend of DKK 3.20 per share. See our latest analysis for ISS. That focus on shareholder returns comes as momentum has been building in the stock, with ISS’s share price at DKK234.0 and a 1 year total shareholder return of 50.89% set against a 5 year total shareholder return of 108.91%. If this kind of shareholder...

Ørsted (CPSE:ORSTED) is back in focus after the Trump administration chose not to appeal a court ruling that allows construction to restart at its Revolution Wind project off Rhode Island. See our latest analysis for Ørsted. Investor sentiment has shifted quickly, with the latest 1 day share price return of 7.03% and 90 day share price return of 25.05% contrasting with a 1 year total shareholder return decline of 8.67%. If you are interested in how policy shifts can affect other parts of the...

Returns snapshot and recent performance A.P. Møller Mærsk (CPSE:MAERSK B) has delivered a 38.25% total return over the past year and 68.67% over the past 3 years, with a 9.56% gain year to date. Shorter term, the stock shows a 1.89% decline over the past day and a 4.37% decline over the past week, while the past month return stands at 2.68% and the past 3 months at 9.94%. See our latest analysis for A.P. Møller - Mærsk. The recent 1 week and 1 day share price declines sit against a stronger...

Recent share performance and business snapshot Ringkjøbing Landbobank (CPSE:RILBA) has seen its share price slip about 10% over the past month and roughly 2% over the past 3 months, inviting closer attention from income and value focused bank investors. The Danish lender focuses on private banking, mortgages, wealth management and broader financial services, all generated domestically, with reported revenue of DKK 4,155.8 million and net income of DKK 2,313.4 million, according to the latest...

Vestas Wind Systems (CPSE:VWS) is back in focus after announcing plans for a nacelle and hub factory in Scotland, which represents a more than €250 million offshore wind investment tied directly to UK auction outcomes. See our latest analysis for Vestas Wind Systems. The planned Scotland factory and recent wind turbine orders in France and Japan come as Vestas’ 7 day share price return of 12.7% contrasts with a negative year to date share price return and mixed multi year total shareholder...

Why Carlsberg (CPSE:CARL B) is on investors’ radar Carlsberg (CPSE:CARL B) has drawn attention after a one‑month return of an 18% decline, alongside a past three‑month drop of 3.2%, prompting investors to reassess the brewer’s valuation and financial profile. See our latest analysis for Carlsberg. At a share price of DKK796.6, Carlsberg’s recent 18% one month share price decline sits alongside a 3.5% year to date share price fall and a 7.3% one year total shareholder return decline, pointing...

Investors may be wondering whether Novo Nordisk’s current share price reflects its true worth, or if the recent weakness is creating a potential value opportunity. The stock last closed at DKK 240.30, with returns of 1.0% over 7 days, a 1.4% decline over 30 days, a 27.2% decline year to date, and a 48.6% decline over 1 year, while the 5-year return stands at 20.2%. These moves sit against a backdrop of ongoing attention on Novo Nordisk’s role in pharmaceuticals and biotech, including...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

Zealand Pharma (CPSE:ZEAL) is setting up a major U.S. research hub in Cambridge, Massachusetts, focused on AI-driven drug discovery and automation. The new site will support work on hybrid therapies, including antibody peptide conjugates and siRNAs, alongside the company’s peptide heritage. The expansion is intended to plug Zealand Pharma directly into the Boston life sciences cluster, with implications for scientific capabilities and hiring. For investors tracking Zealand Pharma at a share...

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...

Bylaw changes and capital structure moves grab investor attention Embla Medical hf (CPSE:EMBLA) has drawn fresh interest after its 2026 Annual General Meeting approved share capital reductions, renewed board authorizations for future capital increases, and set out conditions for new share buyback and employee option programs. See our latest analysis for Embla Medical hf. Despite the AGM activity around buybacks and share capital, Embla Medical hf's share price has eased in recent months, with...

Bavarian Nordic A/S recently reported full-year 2025 results, with sales rising to DKK 6,243.96 million and net income reaching DKK 1,375.38 million, alongside higher earnings per share from continuing operations. A day earlier, the company expanded its partnership with Serum Institute of India to transfer chikungunya vaccine manufacturing and explore further co-development, potentially broadening access in low- and middle-income countries. Next, we’ll assess how the chikungunya tech...

Ørsted (CPSE:ORSTED) has proposed the election of three new board members at its annual general meeting scheduled for April 2026. The nominees are Karen Boesen, Karl Johnny Hersvik, and Samuel Leupold, each bringing experience in energy and renewables. Two current board members are not seeking re election, which would reshape the composition of Ørsted's board if the proposals are approved. For shareholders, these board changes come with Ørsted's share price at DKK144.0 and a mixed return...

Why Coloplast’s CEO transition is in focus Coloplast (CPSE:COLO B) is back on investors’ radar after the board appointed Gavin Wood as President and CEO, effective 1 May 2026, following a year under interim chief Lars Rasmussen. Wood arrives from senior roles at Johnson & Johnson MedTech EMEA and previous leadership positions at Mölnlycke and Ethicon, raising questions about how his background could shape Coloplast’s future direction and its healthcare portfolio. See our latest analysis for...

Københavns Lufthavne (CPSE:KBHL) has wrapped up FY 2025 with Q4 revenue of DKK 1,368 million and basic EPS of DKK 32.95, while trailing twelve month figures sit at DKK 5.5 billion in revenue and EPS of DKK 158.00, reflecting earnings growth of 19.6% over the period. The company has seen quarterly revenue move from DKK 1,245 million and EPS of DKK 24.98 in Q4 2024 to DKK 1,368 million and EPS of DKK 32.95 in Q4 2025, with margins stepping up from 20% to 22%. This puts profitability at the...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...

If you are wondering whether GN Store Nord's current share price reflects its true worth, you are not alone. This article is built to help you make sense of what the market is pricing in. GN Store Nord shares last closed at DKK 87.08, with returns of 6.2% decline over 7 days, 11.8% decline over 30 days, 20.8% decline year to date, 26.3% decline over 1 year, 39.0% decline over 3 years and 81.8% decline over 5 years. These moves may have shifted how investors think about both risk and...